ViroGates is an international medical technology company working with suPAR, which is a biomarker that detects inflammation in the body. It is possible to measure the protein in the blood of everyone. In the beginning of December, the company announced that the Innovation Fund has been assigned a so-called Innobooster grant of DKK 2.8 million for the continued work of developing, testing and subsequently launching a point-of-care product (suPARnostic POC).
The POC product must be able to test both the biomarker suPAR and another biomarker called CRP in less than 10 minutes, which, like suPAR, gives an indication of the level of inflammation in the body. The product must therefore be able to be used as a test in ambulances and in medical practice to quickly assess whether patients should be admitted or not.
The higher the suPAR levels, the more ill you become compared to people with low suPAR levels. Thus, suPAR levels of respectively below 4ng/ml, between 4-6ng/ml, and above 6ng/ml can identify critical patients with a low, medium or high risk of mortality within 30- and 90 days.
The POC product was supposed to be launched in 2021 but has been postponed until Q2’2022. The POC product was supposed to be launched in 2021 but has been postponed until Q2’2022. The delay is related to general analytical performance parameters and a detailed review of development plans with ViroGates’ Austrian partner Genspeed Biotech.
